Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns.
This study aimed to investigate the effect of allopurinol in the management of cerebral hypoxia-ischemia by monitoring nitric oxide levels of serum and cerebrospinal fluid. Sixty asphyxiated infants were divided randomly into two groups. Group I infants (n = 30) received allopurinol (40 mg/kg/day, 3 days) within 2 hours after birth. Group II infants (n = 30) received a placebo. Twenty healthy neonates served as control subjects. Cerebrospinal fluid and serum nitric oxide levels were measured within 0-24 hours and 72-96 hours after birth. Both serum and cerebrospinal fluid concentrations of nitric oxide were higher in severely asphyxiated infants (40.86 +/- 8.97, 17.3 +/- 3.63 micromol/L, respectively) but lower in mildly asphyxiated infants (25.85 +/- 3.57, 5.70 +/- 2.56 micromol/L, respectively) than in moderately asphyxiated infants (35.86 +/- 5.38, 11.06 +/- 3.37 micromol/L, respectively) within the first 0-24 hours after birth. Serum nitric oxide levels in control subjects were lower than those of moderately and severely asphyxiated infants. Serum nitric oxide levels of Group I infants within 72-96 hours after birth decreased significantly from their corresponding levels within 0-24 hours after birth. The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.
Gunes
Tamer
T
Erciyes University, School of Medicine, Department of Pediatrics, Division of Neonatology, Department of Biochemistry, Kayseri, Turkey.
Ozturk
Mehmet Adnan
MA
Koklu
Esad
E
Kose
Kader
K
Gunes
Isin
I
D000493:Allopurinol / Q000008:administration & dosage*; D001238:Asphyxia Neonatorum / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002657:Child Development; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage*; D006801:Humans; D002534:Hypoxia, Brain / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009569:Nitric Oxide / Q000097:blood* / Q000134:cerebrospinal fluid; D010919:Placebos; D016896:Treatment Outcome
D016166:Free Radical Scavengers; D010919:Placebos; D009569:Nitric Oxide; D000493:Allopurinol